SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richard davis who wrote (899)11/17/1996 5:54:00 PM
From: John H. Farro   of 4342
 
Richard, I think you are making a subtle mistake in your analysis which is causing you to paint a slightly overoptimistic evaluation of the AndroCar results. Reread Art Koch's analysis in post 779. Notice that the remark for patinet 2 is "NOW in remission" whereas the remarks for patients 3 and 5 is "REMAINS in remission." I think 2 of the patients were in remission and did not have end stage cancer when they began treatment. Therefore, AndroCar appears to have helped only 3 of the 9 patients. If you eliminate the 2 patients who were in remission from the study, it only helped 3 of 7 patients. Thus, it only helped 42% of the patients with end-stage cancer. This encouraging, but the sample size is so small that it could be a statistical fluke. I will feel a lot better if they can duplicate this result on a larger sample size.

Robin
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News